ORNIDAZOLE

Ornidazole is an antimicrobial agent belonging to the nitroimidazole class of compounds. It was developed to address infections caused by anaerobic bacteria and protozoa, which are organisms that proliferate in environments with low or absent oxygen. Its clinical significance expanded due to its potent activity against pathogens responsible for intestinal, gynaecological, dental, and hepatic infections. The compound entered clinical use in international markets during the early 1970s following completion of clinical safety and efficacy studies. It was subsequently adopted widely across multiple countries for treatment of amoebiasis, giardiasis, trichomoniasis, and anaerobic bacterial infections.

Ornidazole uses for the treatment of : Gastrointestinal infections caused by Giardia, Entamoeba histolytica, and anaerobic bacteria Bacterial vaginosis and pelvic infections Liver abscesses due to anaerobic bacteria. Skin and soft tissue infections caused by anaerobes Prevention of infections following surgical procedures

Oral tablets or suspension for outpatient treatment. Intravenous infusion for hospital-based infection care or when oral therapy is not feasible. Typical dosing frequency is once or twice daily, depending on infection type and severity. IV formulations are infused slowly using compatible fluids under clinical supervision. Therapy duration is usually short-term, commonly 3 to 10 days based on infection and clinical response.

Common Ornida Infusion side effects include: Nausea and vomiting Stomach pain or diarrhoea Headache Metallic taste in the mouth Less common side effects: Dizziness or vertigo Skin rash or itching Neurological effects such as numbness or tingling in extremities (rare) Seek medical attention if severe neurological symptoms, allergic reactions, or persistent gastrointestinal issues occur.

Can cause nervous system-related symptoms such as dizziness, sleepiness, tremors, or rarely seizures in sensitive individuals. Avoid alcohol during treatment, as reactions like flushing, nausea, vomiting or rapid heartbeat may occur. Use carefully if there is a history of neurological disorders, including peripheral neuropathy or epilepsy related conditions. May occasionally lead to blood cell count changes, so monitoring is advised when treatment is prolonged. Hypersensitivity reactions are possible; stop use if symptoms like rash, swelling or breathing difficulty appear.

Assess carefully in those with liver disease, as metabolism occurs mainly through hepatic pathways. Monitor patients who develop tingling, numbness or muscle coordination issues and discontinue if symptoms persist. Caution in elderly patients or those on CNS-acting medications due to additive neurological effects such as drowsiness. Ensure adequate hydration during treatment for parasitic intestinal infections. Use in pregnancy or breastfeeding only when medically advised and clearly needed. Not routinely recommended for long-term therapy unless absolutely required with blood parameter checks.

https://go.drugbank.com/drugs/DB13026 https://www.sciencedirect.com/topics/neuroscience/ornidazole https://precision.fda.gov/ginas/app/ui/substances/6ff13aa2-0a8b-4188-a5d9-e15514fddabe